Matoke Holdings Secures £437.6k to Advance Antimicrobial Wound Care Technology

Matoke Holdings Limited, a British biotechnology company based in Southmoor, has successfully raised £437.6k in its latest funding round. The allotment date for this capital injection was 13 March 2026, with the filing date recorded as 27 April 2026. This funding will support the company's ongoing development of its proprietary Reactive Oxygen® technology, aimed at revolutionising antimicrobial solutions for wound care and infection control.

Founded on 4 February 2010, Matoke Holdings Limited addresses the critical global challenge of antimicrobial resistance (AMR) and the persistent need for effective wound management. The company specialises in developing innovative antimicrobial products, encompassing both medicinal/pharmaceutical and medical device categories, for clinicians treating acute, surgical, and chronic wounds. Its core mission is to deliver effective, safe, scalable, and practical solutions to combat antibiotic resistance and enhance patient outcomes. Matoke Holdings collaborates with leading researchers at British universities and teaching hospitals to advance its products from discovery through to manufacture, regulatory approval, and early clinical use.

The company's latest accounts indicate an employee count of 9, while its LinkedIn profile suggests a more current team size of 19 individuals. Financial metrics such as revenue and profit/loss figures were not disclosed in the available data.

This recent £437.6k round follows a series of previous funding activities for Matoke Holdings. In 2025, the company secured £736k on 19 December and £1m on 29 April. Prior to that, 2024 saw two rounds: £1m on 2 December and £500k on 15 March. The company also raised several smaller amounts in 2023, including £212.5k on 30 June, £110.5k on 7 July, £50k on 25 July, £50k on 25 September, £60k on 6 October, and £40k on 21 December. This latest funding round, while smaller than some of its immediate predecessors, continues Matoke Holdings' consistent capital acquisition to fuel its research and development efforts.

The funding landscape for biotechnology and health technology companies in the UK, particularly those focused on areas like antimicrobial resistance and wound care, has shown dynamic trends. In 2025, the UK biotech sector faced a challenging financing environment, securing £1.9 billion in equity financing, with venture capital accounting for £1.8 billion, marking a 13.2% decrease year-on-year. This decline was attributed to a drop in deal activity, as investors became highly selective. However, there was a stronger finish to 2025, with the fourth quarter recording the highest quarterly deal count of the year, suggesting improving investor confidence.

Entering 2026, the UK biotech sector has shown signs of recovery. In the first quarter of 2026, total equity financing reached £552 million, an increase from £466 million in Q4 2025. Venture capital was a primary driver, rising 17% quarter-on-quarter to £516 million, indicating growing investor confidence. Deal activity also surged, with 25 VC transactions, a 67% year-on-year increase, pointing to a more active funding environment. Notably, the UK secured 57% of all European biotech venture capital in Q1 2026.

Within Matoke Holdings' specific domain, there is significant public and private investment. The NHS allocates approximately £8.3 billion annually to wound care, surpassing the combined costs of obesity and cancer. Recognising this need, the University of Hull is establishing a £48 million Wound Innovation Centre (WIC) in East Yorkshire, backed by £16 million from the UK Research Partnership Investment Fund and matched industry funding from partners like Polaroid Therapeutics and Reckitt. This initiative aims to become a global hub for advanced research and treatment in wound care.

Furthermore, initiatives targeting antimicrobial resistance are receiving substantial support. PACE (Pathways to Antimicrobial Clinical Efficacy), a major UK public-private collaboration involving Innovate UK, LifeArc, and Medicines Discovery Catapult, recently launched a £6 million funding round for early-stage antibacterial therapeutics, as part of a broader £30 million investment to accelerate solutions for global AMR challenges. The Global AMR Innovation Fund (GAMRIF) also supports early-stage research in underfunded areas of AMR, with partnerships and investments in various programmes. Imperial's Fleming Initiative, for example, secured £3.1 million in new funding for breakthrough research to transform antibiotic discovery. Additionally, the UK Defence Innovation (UKDI) launched a competition offering up to £1.5 million for innovations in conflict wound care.

The broader UK healthcare outlook for 2026, as highlighted by Barclays, indicates strong demand for healthcare services and a significant acceleration in technology adoption. Average tech investment across the sector rose by 20% in 2025, with continued momentum expected into 2026, and 86% of healthcare leaders planning to increase AI investment. The Labour government's 10-year health plan for the NHS, published in July 2025, also prioritises digital-first healthcare, proactive care, and community-based care, with major investment in AI, data, and automation, creating substantial growth opportunities for health tech innovators. This supportive environment underscores the strategic importance of companies like Matoke Holdings in addressing critical healthcare needs through technological innovation.